BioXcel Therapeutics is trading 9.63% up in after-hours trading at $0.12 after continued volatility following its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva.
- The transaction includes $57.5 million upfront and potential milestone payments.
- The company seeks up to $19 million in debtor-in-possession financing.
- The gain follows a 21.90% decline on September 2, 2026, reflecting restructuring-related trading activity rather than a newly identified announcement.